Del buys X-Ray Technologies
Del Global Technologies has acquired X-Ray Technologies, a developer of low-cost x-ray systems for the private-office, veterinary, and chiropractic markets. Del has integrated its purchase into its Universal product line to form a new division,
Del Global Technologies has acquired X-Ray Technologies, a developer of low-cost x-ray systems for the private-office, veterinary, and chiropractic markets. Del has integrated its purchase into its Universal product line to form a new division, Universal/X-Tek, that will sell products under the Universal and X-Tek trade names.
X-Ray Technologies was founded in 1994 and began selling systems in 1996. The company's products include lightweight full-body x-ray systems that sell in the range of $10,000 to $15,000, making them cost-effective for smaller medical facilities, according to Leonard Trugman, Del chairman, CEO, and president. X-Ray Technologies had revenues of over $1 million last year, Trugman said.
Del believes it can boost sales of the X-Ray Technologies product line by plugging the systems into the Del distribution network. Del is especially enthusiastic about the potential of the systems in international markets, such as in developing countries.
As part of the acquisition, X-Ray Technologies president and founder Randy Duffy will be general manager of the Universal/X-Tek division, reporting to John Mankowich, vice president and general manager of Del's Gendex-Del Medical Imaging subsidiary.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
